InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Inovio Pharmaceuticals Inc (NASDAQ: INO ) reported its latest quarterly earnings results after the bell Wednesday, with revenue and earnings rising year-over-year.
Inovio Pharmaceuticals reported total revenue for its fourth quarter of $8.8 million, a 3.5% gain compared to the year-ago quarter of $8.5 million. For the full year, the company's revenue reached $42.2 million, beating the $35.4 million from the year-ago quarter, rising more than 19% compared to the year-ago quarter.
The company's total operating expenses for the quarter were $31.7 million, ahead of the year-ago total of $30.9 million. For the full fiscal year, this figure was $125.9 million, topping the year-ago total operating expenses of $111.6 million.
Inovio Pharmaceutical's research and development expenses for the quarter came in at $24.6 million, and they were $98.6 million for the fiscal year 2017. In the year-ago period and year, they were $23.9 million and $88.7 million respectively. This increase in expenses was linked with a rise in the company's headcount.
INO shares were trading flat after the bell.
More From InvestorPlace
- 7 Great REITs to Own in Good Times and Bad
- 8 Companies That Could Disappear by 2019
- 10 Dividend Stocks to Buy With Low Yields, But Big Dividend Growth
The post Inovio Pharmaceuticals Inc (INO) Q4 Revenue Grew 3.5% Year-Over-Year appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
